Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators. Ständer S, et al. Among authors: pink a. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4796. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602139
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis.
Ferris LK, Bagel J, Huang YH, Pink AE, Tyring SK, Kokolakis G, DeLozier AM, Li S, Shen YK, Iaconangelo C, Ota T, Bissonnette R. Ferris LK, et al. Among authors: pink ae. J Am Acad Dermatol. 2024 Nov 14:S0190-9622(24)03152-9. doi: 10.1016/j.jaad.2024.10.076. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39549848 Free article.
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.
Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA, Lane M, Langan SM, Laws P, O'Driscoll D, O'Kane D, Payne A, Petrof G, Pink AE, Rauz S, Robbie S, Gore SK, Shah M, Woolf RT, Wang C, Tumbeva S, Mohd Mustapa MF. Ardern-Jones MR, et al. Among authors: pink ae. Br J Dermatol. 2024 Nov 18;191(6):865-885. doi: 10.1093/bjd/ljae344. Br J Dermatol. 2024. PMID: 39236226 Review.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE, Carrascosa JM, Rewerska B, Szepietowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S, Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C; ARCADIA 1 and ARCADIA 2 Study Investigators. Silverberg JI, et al. Among authors: pink ae. Lancet. 2024 Aug 3;404(10451):445-460. doi: 10.1016/S0140-6736(24)01203-0. Epub 2024 Jul 24. Lancet. 2024. PMID: 39067461 Clinical Trial.
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Rademaker M, Fomina D, Gutermuth J, Ahn J, Valenzuela F, Ameen M, Steinhoff M, Kirchhof MG, Lio P, Wollenberg A. Silverberg JI, et al. Among authors: pink ae. J Eur Acad Dermatol Venereol. 2024 Nov;38(11):2139-2148. doi: 10.1111/jdv.20229. Epub 2024 Jul 11. J Eur Acad Dermatol Venereol. 2024. PMID: 38989857
A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis.
Hernandez-Cordero A, Thomas L, Smail A, Lim ZQ, Saklatvala JR, Chung R, Curtis CJ, Baum P, Visvanathan S, Burden AD, Cooper HL, Dunnill G, Griffiths CEM, Levell NJ, Parslew R, Reynolds NJ, Wahie S, Warren RB, Wright A; APRICOT and PLUM Study Team; Simpson M, Hveem K, Barker JN, Dand N, Løset M, Smith CH, Capon F. Hernandez-Cordero A, et al. J Allergy Clin Immunol. 2024 Sep;154(3):657-665.e9. doi: 10.1016/j.jaci.2024.05.015. Epub 2024 May 28. J Allergy Clin Immunol. 2024. PMID: 38815935 Free article.
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Simpson EL, et al. Among authors: pink ae. Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2. Dermatol Ther (Heidelb). 2024. PMID: 38696027 Free PMC article.
120 results